Ocular Therapeutix, Inc. (OCUL)
10.45
-0.04
(-0.38%)
USD |
NASDAQ |
Sep 01, 11:11
Ocular Therapeutix Total Long Term Debt (Quarterly) : 76.26M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 76.26M |
| March 31, 2026 | 76.29M |
| December 31, 2025 | 74.15M |
| September 30, 2025 | 74.25M |
| June 30, 2025 | 74.31M |
| March 31, 2025 | 74.07M |
| December 31, 2024 | 73.85M |
| September 30, 2024 | 73.41M |
| June 30, 2024 | 73.23M |
| March 31, 2024 | 72.86M |
| December 31, 2023 | 81.80M |
| September 30, 2023 | 81.14M |
| June 30, 2023 | 63.06M |
| March 31, 2023 | 62.79M |
| December 31, 2022 | 62.68M |
| September 30, 2022 | 49.50M |
| June 30, 2022 | 49.87M |
| March 31, 2022 | 50.33M |
| December 31, 2021 | 57.36M |
| September 30, 2021 | 51.22M |
| June 30, 2021 | 51.67M |
| March 31, 2021 | 55.19M |
| December 31, 2020 | 57.08M |
| September 30, 2020 | 52.95M |
| June 30, 2020 | 56.41M |
| Date | Value |
|---|---|
| March 31, 2020 | 56.25M |
| December 31, 2019 | 58.22M |
| September 30, 2019 | 55.84M |
| June 30, 2019 | 57.44M |
| March 31, 2019 | 55.53M |
| December 31, 2018 | 24.79M |
| September 30, 2018 | 14.17M |
| June 30, 2018 | 15.63M |
| March 31, 2018 | 17.08M |
| December 31, 2017 | 18.02M |
| September 30, 2017 | 17.92M |
| June 30, 2017 | 17.82M |
| March 31, 2017 | 17.72M |
| December 31, 2016 | 15.64M |
| September 30, 2016 | 15.55M |
| June 30, 2016 | 15.46M |
| March 31, 2016 | 15.36M |
| December 31, 2015 | 15.27M |
| September 30, 2015 | 15.13M |
| June 30, 2015 | 15.04M |
| March 31, 2015 | 14.95M |
| December 31, 2014 | 14.86M |
| September 30, 2014 | 14.78M |
| June 30, 2014 | 14.68M |
| March 31, 2014 | 2.003M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| EyePoint, Inc. | 19.81M |
| LENZ Therapeutics, Inc. | 0.122M |
| Merck & Co., Inc. | 51.08B |
| Theravance Biopharma, Inc. | 60.57M |
| ANI Pharmaceuticals, Inc. | 610.49M |